HC Wainwright & Co. Reiterates Buy on Blueprint Medicines, Maintains $135 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating for Blueprint Medicines (NASDAQ:BPMC) and maintained a price target of $135.
October 31, 2024 | 12:13 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright & Co. analyst Andrew Fein has reiterated a Buy rating for Blueprint Medicines and maintained a price target of $135, indicating confidence in the company's future performance.
The reiteration of a Buy rating and maintenance of a $135 price target by a reputable analyst suggests positive sentiment and confidence in Blueprint Medicines' future performance, likely leading to a positive short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100